How Novo Is Combatting Lilly's New Pill Before It Launches - Investor's Business Daily

How Novo Is Combatting Lilly's New Pill Before It Launches  Investor's Business DailyNovo says indirect data favour its Wegovy pill over Lilly's new obesity entrant  FirstWord PharmaNovo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison  CNBCWegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026  PR NewswireApprovals in Hand, Lilly and Novo Obesity Pills Will Battle It Out on Hairline Differences  BioSpace